Iterum Therapeutics plc(ITRM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.9M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ITRM Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Iterum Therapeutics plc (ITRM), a Healthcare sector company. ITRM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.9m in revenue. Based on the latest XBRL financial filings (Q3 2025), Iterum Therapeutics plc reports net income of $-9.0M, free cash flow of $-7.5M. Top institutional holders of ITRM by reported 13-F value include CAPTRUST FINANCIAL ADVISORS, Gen-Wealth Partners, Jump Financial,, based on the most recent SEC filings. ITRM trades on the Nasdaq exchange and files with the SEC under CIK 1659323. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ITRM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Iterum Therapeutics plc directly from SEC EDGAR.
Net Income
Q3 2025
$-9.0M
Free Cash Flow
Q3 2025
$-7.5M
ROIC
Q3 2025
-61.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+35.4% YoYOperating Income
+60.6% YoYEPS (Diluted)
+57.4% YoYTotal Assets
+69.8% YoYTotal Debt
+172.6% YoYOp. Cash Flow
+31.9% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 -100.0% | $869.0K |
| Net Income | $-24.8M +35.4% | $-38.4M +13.6% | $-44.4M +51.5% | $-91.6M +0.0% | $-91.6M -18.8% | $-77.1M |
| Operating Income | $-18.7M +60.6% | $-47.5M -56.2% | $-30.4M -23.8% | $-24.5M +23.6% | $-32.1M +58.0% | $-76.6M |
| EPS (Diluted) | $-1.26 +57.4% | $-2.96 +18.5% | $-3.63 +56.8% | $-8.41 +74.1% | $-32.49 | — |
| Total Assets | $44.6M +69.8% | $26.3M -60.7% | $66.8M -27.0% | $91.5M +179.1% | $32.8M -66.5% | $97.9M |
| Total Debt | $31.2M +172.6% | $11.5M -9.9% | $12.7M +48.5% | $8.6M -70.3% | $28.8M +104.5% | $14.1M |
| Operating Cash Flow | $-26.8M +31.9% | $-39.3M -112.9% | $-18.5M -16.6% | $-15.8M +70.9% | $-54.5M +29.4% | $-77.3M |
Get alerted when ITRM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Iterum Therapeutics plc including:
Top Institutional Holders of ITRM
CAPTRUST FINANCIAL ADVISORS
$4.2K138,600 shGen-Wealth Partners Inc
$2.5K82,617 shJump Financial, LLC
$2.2K72,156 shKrilogy Financial LLC
$1.7K69,761 shXTX Topco Ltd
$1.5K49,380 shMAI Capital Management
$1.1K35,000 shFLAGSHIP HARBOR ADVISORS, LLC
$600.0020,000 shMORGAN STANLEY
$471.0015,713 shUBS Group AG
$96.003,201 shMedallion Wealth Advisors, LLC
$50.001,680 sh
| Fund | Value | Shares |
|---|---|---|
| CAPTRUST FINANCIAL ADVISORS | $4.2K | 138,600 |
| Gen-Wealth Partners Inc | $2.5K | 82,617 |
| Jump Financial, LLC | $2.2K | 72,156 |
| Krilogy Financial LLC | $1.7K | 69,761 |
| XTX Topco Ltd | $1.5K | 49,380 |
| MAI Capital Management | $1.1K | 35,000 |
| FLAGSHIP HARBOR ADVISORS, LLC | $600.00 | 20,000 |
| MORGAN STANLEY | $471.00 | 15,713 |
| UBS Group AG | $96.00 | 3,201 |
| Medallion Wealth Advisors, LLC | $50.00 | 1,680 |
More Healthcare Companies
View all Healthcare →Put ITRM on your watchlist
Track score changes the day Iterum Therapeutics plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ITRM a good stock to buy?
13F Pro's AI-powered analysis of Iterum Therapeutics plc (ITRM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ITRM are available on the ITRM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ITRM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ITRM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Iterum Therapeutics plc's investment landscape.